Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)

@inproceedings{Klotz2015AssessmentOI,
  title={Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)},
  author={Luisa Klotz and Berit Gr{\"u}tzke and Maria Eveslage and Michael Deppe and Catharina Christiane Gro\ss and Lucienne Kirstein and Anita Posevitz-Fejf{\'a}r and Tilman Schneider-Hohendorf and Nicholas Schwab and Sven G. Meuth and Heinz Wiendl},
  booktitle={BMC neurology},
  year={2015}
}
BACKGROUND In light of the increased risk of progressive multifocal encephalopathy (PML) development under long-term treatment with the monoclonal antibody natalizumab which is approved for treatment of active relapsing remitting multiple sclerosis (RRMS), there is a clear need for alternative treatment options with comparable efficacy and reduced PML risk… CONTINUE READING